Want to join the conversation?
$AKRX is maintaining its full-year 2016 financial guidance inclusive of net revenue of $1,060-1,080MM, GAAP diluted EPS of $1.56-1.66, and adjusted diluted EPS of $2.10-2.20. The guidance contemplates launches of products approved by the U.S. FDA as of May 10, 2016 along with the full year contribution of products launched in 2015.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?